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Abstract: Cardiovascular disease (CVD) is one of the main causes of mortality worldwide, 
and dyslipidemia is a major risk factor for CVD. Ginseng has been widely used in the 
clinic to treat CVD. Ginsenoside Rg3, one of the major active components of ginseng, has 
been reported to exhibit antiobesity, antidiabetic, and cardioprotective effects. However, 
the effect of ginsenoside Rg3 on hepatic lipid metabolism remains unclear. Therefore, we 
investigated  whether  ginsenoside  Rg3  would  regulate  hepatic  lipid  metabolism  with  
AMP-activated  protein  kinase  (AMPK)  activation  in  HepG2  cells.  Ginsenoside  Rg3 
significantly reduced hepatic cholesterol and triglyceride levels. Furthermore, ginsenoside 
Rg3 inhibited expression of sterol regulatory element binding protein-2 (SREBP-2) and  
3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). Ginsenoside Rg3 increased 
activity of AMPK,  a major regulator of energy metabolism.  These results  suggest  that 
ginsenoside  Rg3  reduces  hepatic  lipid  accumulation  with  inhibition  of  SREBP-2  and 
HMGCR  expression  and  stimulation  of  AMPK  activity  in  HepG2  cells.  Therefore, 
ginsenoside Rg3  may  be beneficial  as  a  food ingredient to  lower the  risk  of CVD by 
regulating dyslipidemia. 
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1. Introduction  
Cardiovascular disease (CVD) is one of the major causes of mortality globally, and the mortality 
from CVD has been increasing at an alarming rate. The World Health Organization estimates that 
deaths due to CVD will rise to 23.6 million by 2030, which it is an approximate 40% increase from 
2004 rates [1,2]. Dyslipidemia, including high concentrations of total cholesterol and triglycerides, is a 
high risk factor for CVD [1]. In the field of food science, studies on CVD concerned with dyslipidemia 
have  focused  on  food  ingredients  that  have  the  potential  to  reduce  and  regulate  cholesterol  and 
triglyceride concentrations. 
Ginseng is one of the most well-known herbal medicines in the world [3]. Ginsenosides, the major 
pharmacologically-active components of ginseng, are known for their biological activities and can be 
divided into several different compounds, such as Rg3, Rb2, Rc, and Rg1 [3]. Among ginsenosides, 
ginsenoside  Rg3  exhibits  antiobesity  [4],  antidiabetic  [5,6],  anticancer,  antihypertensive,  and 
cardioprotective effects [7]. Ginsam, which is enriched in the ginsenoside Rg3, shows weight-lowering 
effects in an obese insulin-resistant animal model by changing the expression of genes involved in 
glucose and fatty acid metabolism [8]. Treatment with ginsenoside Rg3 is very effective for inhibiting 
lipid accumulation in 3T3-L1 adipocytes compared to that of Rk1 or Rg5 [9]. Nevertheless, it remains 
unresolved  how  ginsenoside  Rg3  inhibits  hepatic  lipid  accumulation  and  whether  it  regulates  the 
expression of sterol regulatory element binding protein-2 (SREBP-2) and activation of AMP-activated 
protein kinase (AMPK) in HepG2 cells. 
SREBP-2  plays  an  important  role  in  the  regulation  of  cholesterol  homeostasis  by  binding  and 
activating  the  promoters  of  SREBP-2-regulated  genes,  such  as  low-density  lipoprotein  receptor  
(LDL-R), 3’-hydroxylmethyl glutaryl coenzyme A synthase (HMGCS) and 3’-hydroxylmethyl glutaryl 
coenzyme A reductase (HMGCR) [10]. LDL-R is primarily responsible for the uptake of LDL from  
the  circulation.  In  contrast,  HMGCS  and  HMGCR  are  major  enzymes  in  hepatic  cholesterol  
biosynthesis  [11].  Thus,  SREBP-2  activation  stimulates  cholesterol  uptake  into  the  cells  and 
cholesterol biosynthesis via up-regulation of LDL-R and HMGCR gene expression. 
AMPK is a key sensor in the regulation of glucose and lipid metabolism. AMPK is found in all 
eukaryotes and is activated by an increase in the cellular AMP:ATP ratio after ATP depletion [12]. 
Once activated, AMPK switches off anabolic pathways such as cholesterol, fatty acid, and triglyceride 
biosynthesis [13]. In the liver, AMPK inactivates key lipid biosynthesis enzymes such as acetyl-CoA 
carboxylase-α  (ACC-α)  and  HMGCR,  which  regulate  fatty  acid  and  cholesterol  biosynthesis, 
respectively [14]. Ginseng extract increases adiponectin protein expression in 3T3-L1 adipocytes [5]. 
The finding that adiponectin activates AMPK and reduces cholesterol synthesis in ApoE-deficient 
mice suggests that the regulation of HMGCR via AMPK may be critical for regulating cholesterol 
metabolism in vivo [14]. Therefore, it is logical to hypothesize that AMPK may be involved in the 
ginsenoside Rg3-induced hypolipidemic effects by reducing triglyceride and cholesterol levels. This Int. J. Mol. Sci. 2012, 13  5731 
 
 
study was designed to investigate the hypolipidemic effects of ginsenoside Rg3 in HepG2 cells. We 
hypothesized that treatment with ginsenoside Rg3 inhibits cholesterol and triglyceride accumulation 
with stimulation of AMPK activity and inhibition of SREBP-2 expression in HepG2 cells. 
2. Results and Discussion  
2.1. Effect of Ginsenoside Rg3 on HepG2 Cell Viability 
HepG2 cells were used to confirm that ginsenoside Rg3 has inhibitory effects on lipid accumulation. 
Cells  were  cultured  in  various  concentrations  of  Rg3  for  8,  24,  and  48  h  to  determine  whether 
ginsenoside Rg3 affects HepG2 cell viability. The survival rates of HepG2 cells were unaffected in 1 
or 10 µM Rg3 after 48 h incubation (Figure 1) (P < 0.05). In contrast, high doses (50–100 µM) of Rg3 
decreased  viability  by  25–60%  after  48  h  of  incubation.  Thus,  the  nontoxic  concentrations  were  
1–10 µM ginsenoside Rg3 in HepG2 cells. 
Figure 1. Effect of ginsenoside Rg3 on HepG2 cell viability. Cells were treated with 0 
(control), 1, 10, 50, or 100 µM ginsenoside Rg3, and incubated for 8, 24, or 48 h. Cell 
viability was determined using the WST-8 assay. Values are expressed as mean ±  SE (n = 3) 
of three independent experiments. * P < 0.05 and ** P < 0.01 versus control treatment. 
 
Meticulous care is required when treating cells  with ginsenoside Rg3, because cytotoxicity has  
been  reported  in  several  in  vitro  studies.  Ginsenoside  Rg3  exhibits  IC50  (50%  growth  inhibition 
concentration) values of 41 µM  in  SK-HEP-1  hepatoma  cancer  cells  [15] and potent cytotoxicity 
against HepG2 cells, with an IC50 value of approximately 50 µM after a 36 h incubation [16]. A recent 
study reported that HepG2 cell viability decreased following treatment with 50, 100, or 200 µ g/mL Rg3 
for 24 h [17]. However, cell viability remained at 90–100% in Rg3 concentrations below 10 µM  in the 
present study. Thus, a ginsenoside Rg3 concentration of 10 µM was used in subsequent experiments. 
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2.2. Effects of Ginsenoside Rg3 on Lipid Metabolism 
We  investigated  intracellular  cholesterol  and  triglyceride  contents  to  evaluate  the  effects  of 
ginsenoside  Rg3  on  the  reduction  of  cholesterol  and  triglyceride.  HepG2  cells  were  treated  with  
10 µM ginsenoside Rg3 for 8 or 24 h. The amount of cholesterol in HepG2 cells in the presence of 
ginsenoside  Rg3  was  significantly  reduced  by  36%  in  comparison  with  the  control  after  a  24  h 
incubation (Figure 2a). The HepG2 intracellular triglyceride content in the presence of ginsenoside 
Rg3 also decreased by 15% compared with that of HepG2 cells in the absence of ginsenoside Rg3 
(Figure 2b). Previous studies reported that treatment with high concentrations of  ginsenoside Rg3  
(40–100 µM) reduce intracellular triglyceride accumulation in 3T3-L1 adipocytes [4,9]. Hwang et al. 
suggested that ginsenoside Rg3 is effective in inhibiting lipid biosynthesis by up-regulating AMPK [4]. 
Treatment with ginsenoside Rg3 results in a decrease in blood cholesterol and triglyceride levels in 
hyperlipidemic mice [5] and in obese type 2 diabetic rats [18]. Treatment with Korean red ginseng 
extract, which is enriched with ginsenoside Rg3, reduces the serum total cholesterol level in C57BL/6J 
mice fed a high-fat diet by down-regulating lipid-metabolism associated genes such as cholesterol  
7α-hydroxylase (CYP7A1), which catalyzes the synthesis of cholesterol, steroids, and other lipids [19]. 
In this study, ginsenoside Rg3 reduced cholesterol and triglyceride accumulation in HepG2 cells. 
Figure 2. Effects of ginsenoside Rg3 on cholesterol (a) and triglyceride (b) contents in 
HepG2  cells.  Cells  were  incubated  with  10  µM  ginsenoside  Rg3  for  8  or  24  h.  The 
intracellular cholesterol and triglyceride contents were determined by enzymatic methods. 
Values are expressed as mean ±  SE (n = 3) of three independent experiments. * P < 0.05 
and ** P < 0.01 versus control treatment. 
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Figure 2. Cont. 
 
(b) 
2.3. Effects of Ginsenoside Rg3 on Gene Expression of SREBP-2 and HMGCR 
Cellular cholesterol and fatty acid homeostasis is regulated by three members of the SREBP family, 
namely SREBP-1a, SREBP-1c, and SREBP-2. SREBP-2 primarily regulates cholesterol metabolism 
by  activating  genes  required  for  cholesterol  biosynthesis  such  as  HMGCS,  HMGCR,  farnesyl 
diphosphate synthase, and squalene synthase [20]. Nascent SREBP-2 is synthesized as an inactive 
precursor protein bound to the endoplasmic reticulum membrane [10]. When cells are deprived of 
sterols, a two-step proteolytic process releases the SREBP-2 NH2-terminal fragment as a mature form 
of SREBP-2, and it binds to sterol regulatory elements in the promoter regions of genes involved in 
cholesterol biosynthesis [21]. A previous in vivo study reported that mRNA levels of all SREBP-2 
target genes, such as LDL-R, HMGCS, and HMGCR, decrease with a decrease in SREBP-2 mRNA 
level in SREBP cleavage-activating protein-deficient mice [22]. 
Food ingredients, such as curcumin [11], skim milk, casein, whey, leucine, and valine [23], interfere 
with  SREBP-2  mRNA  expression,  leading  to  a  reduction  in  the  cellular  cholesterol  level.  These 
previous  studies  indicate  that  inhibiting  SREBP-2  expression  may  be  involved  in  the  decrease  of 
cellular  cholesterol  level.  However,  the  regulatory  effects  of  ginsenoside  Rg3  on  SREBP-2  and 
HMGCR gene expression involved in lipid metabolism have not been reported in HepG2 cells. 
We investigated the mRNA expression of SREBP-2 and HMGCR to understand the mechanism that 
underlies the hypolipidemic effect of ginsenoside Rg3 in HepG2 cells. Ginsenoside Rg3 decreased 
mRNA  expression  of  SREBP-2,  a  major  direct  transcriptional  regulator  of  genes  involved  in 
cholesterol  metabolism,  in  dose-  and  time-dependent  manners  (Figure  3a,b).  Gene  expression  of 
HMGCR,  which  catalyzes  a  rate-limiting  step  in  cholesterol  synthesis,  was  also  suppressed  in  
a  time-dependent  manner  (Figure  3c).  Our  results  indicate  that  ginsenoside  Rg3  down-regulated 
SREBP-2  and  HMGCR  mRNA  expression.  Consequently,  inhibiting  cholesterol  biosynthesis  by 
down-regulating SREBP-2 and HMGCR mRNA expression may be evidence for the hypothesis that 
ginsenoside Rg3 has a hypolipidemic effect in HepG2 cells.  
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Figure 3. Effects of ginsenoside Rg3 on SREBP-2 (a), (b) and HMGCR (c) expression in 
HepG2  cells.  Cells  were  treated  with  different  concentrations  (0,  0.1, 0  or  10  µM)  of 
ginsenoside Rg3 for 24 h and were treated with 10 µM of ginsenoside Rg3 for 8 or 24 h. 
The mRNA of SREBP-2 and HMGCR were determined by quantitative real-time PCR. 
Values are expressed as mean ±  SE (n = 3) of three independent experiments. * P < 0.05 
and ** P < 0.01 versus control treatment. 
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2.4. Effect of Ginsenoside Rg3 on AMPK Activation  
AMPK  activation  regulates  energy  metabolism  that  favors  the  inhibition  of  lipogenesis  by 
inactivating ACC-α and HMGCR, the key enzymes of fatty acid synthesis and cholesterol synthesis, 
respectively [14]. Inactivation of ACC-α by AMPK reduces malonyl-CoA concentration, leading to 
stimulation of fatty acid oxidation concomitantly with an increase in ß -oxidation [24]. Treatment with 
metformin,  an  AMPK  substrate,  stimulates  AMPK  activity,  which,  in  turn,  decreases  intracellular 
triglyceride and cholesterol contents in HepG2 cells [13]. In the cholesterol biosynthesis pathway, 
AMPK inhibits the conversion of HMG-CoA to mevalonate by down-regulating HMGCR [24]. 
We treated cells with ginsenoside Rg3 to investigate whether it affects AMPK activity in HepG2 
cells. As a result, AMPK activity increased by 1.22- and 1.58-fold in HepG2 cells treated with 1 and 
10 µM ginsenoside Rg3, respectively, compared with that in control cells (P < 0.05) (Figure 4). It has 
been reported that AMPK activation is involved in the reduction of triglyceride accumulation by Rg3 
during 3T3-L1 adipocyte differentiation [4]. Similarly, a previous in vivo study showed that treatment 
with ginsam, which is a component of ginseng produced by vinegar extraction and enriched with 
ginsenoside Rg3, reduces plasma total cholesterol concentration by increasing AMPK activity in obese 
insulin-resistant  rats  [8].  Our  results  suggest  that  ginsenoside  Rg3  may  inhibit  accumulation  of 
triglyceride and cholesterol with stimulating AMPK activity. 
Figure 4. Effect of ginsenoside Rg3 on AMPK activity in HepG2 cells. Cells were treated 
with various concentrations (0, 0.1, 1, or 10 µ M) of ginsenoside Rg3 for 24 h. AMPK 
activity  was  determined  using  an  AMPK  Kinase  Assay  Kit.  Values  are  expressed  as  
mean ±  SE (n = 3) of three independent experiments. * P < 0.05 versus control treatment. 
 
A  recent  study  demonstrated  that  a  synthetic  polyphenol,  S17834,  stimulates  AMPK  activity, 
inhibits SREBP-2 gene expression, and reduces expression of its own target genes, such as HMGCS 
and HMGCR, then down-regulates cholesterol biosynthesis in the liver [25]. Although it was found 
that AMPK activation and down-regulation of SREBP-2 were involved in the hypolipidemic effects 
exerted by the Rg3, no direct correlation was presented between the AMPK and SREBP-2 signaling 
pathways. Therefore, a possible connection between these two effects by ginsenoside Rg3 should be 
investigated in further studies.  
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Our results suggest that the hypolipidemic effects of ginsenoside Rg3 may be caused, at least in part, 
by modulating the expression of SREBP-2 and AMPK activation. To our knowledge, the present study 
is the first to suggest that ginsenoside Rg3 plays a role as a regulator of the expression of SREBP-2 
and AMPK activation involved in lipid metabolism in HepG2 cells. 
3. Experimental Section  
3.1. Reagents 
Ginsenoside Rg3 (purity >98%) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). The human HepG2 cell line was obtained from American Type Culture Collection (Manassas, 
VA, USA). Dulbecco’s modified Eagle’s medium (DMEM), phosphate-buffered saline, pH 7.4 (PBS), 
fetal  bovine  serum  (FBS),  glutamine,  and  penicillin-streptomycin,  TRIzol  reagent,  and  M-MLV 
reverse transcriptase were purchased from Gibco/Invitrogen (Grand Island, NY, USA). The Universal 
SYBR Green PCR Master Mix was obtained from Qiagen (Valencia, CA, USA). A cell count kit-8 
(CCK-8) was purchased from Dojindo Laboratories (Kumamoto, Japan). Assay kits for cholesterol and 
triglyceride were obtained from Asan Pharmaceutical Co. (Seoul, Korea). The AMPK Kinase Assay 
kit was purchased from Cyclex (Nagano, Japan). A bicinchoninic acid (BCA) protein assay kit was 
obtained  from  Thermo  Scientific  (Pittsburgh,  PA,  USA).  Dimethyl  sulfoxide  (DMSO)  and  Triton  
X-100 were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
3.2. Cell Culture 
Human  HepG2  cells  were  cultured  in  DMEM,  supplemented  with  10%  (v/v)  FBS  and  
penicillin-streptomycin  (100  units/mL)  at  37  ° C  and  5%  CO2.  Ginsenoside  Rg3  was  dissolved  in 
DMSO.  The  final  DMSO  concentration  in  culture  medium  was  0.01%.  Cells  were  treated  with 
different concentrations of ginsenoside Rg3 in serum-free media for 8 and 24 h. Control cells were 
treated with 0.01% DMSO without ginsenoside Rg3. All measurements were performed in triplicate 
for each treatment. 
3.3. Cytotoxicity Assay 
Cell viability was determined by the WST-8 [2-(2-methoxy-4-nitropheyl)-3-(4-nitrophenyl)-5-(2,4-
dinitrophenyl)-2H-tetrazolium,  monosodium  salt]  assay,  using  a  CCK-8  kit  according  to  the 
manufacturer’s  instructions.  The assay is  based on the cleavage of the WST-8 tetrazolium salt to 
formazan by cellular mitochondrial dehydrogenase. Cell viability was determined following culture in 
96-well plates at a seeding density of 10
4 cells/well. Cells were treated with 0, 1, 10, 50, or 100 µM of 
ginsenoside Rg3 for 8, 24, and 48 h at 37 ° C. WST-8/1-methoxy-phenazine methosulfate solution was 
added to each well and incubated for 3 h at 37 ° C. The absorbance at 450 nm was measured using a 
Varioskan plate reader (Thermo Electron, Waltham, MA, USA). Values are expressed as a percentage 
of control cells without ginsenoside Rg3 supplementation. 
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3.4. Cholesterol and Triglyceride Assay 
Cells were lysed in a lysis buffer consisting of 1% Triton X-100 in PBS, and the cellular cholesterol 
and  triglyceride  were  measured  using  enzymatic  colorimetric  assay  kits.  The  cellular  protein 
concentration was determined using a BCA protein assay kit. Cellular cholesterol and triglyceride were 
normalized to cellular protein content.  
3.5. Quantitative Real-Time Polymerase Chain Reaction (PCR) 
Total RNA was extracted from HepG2 cells using TRIzol reagent. Complimentary DNAs were 
synthesized  from  4  µg  of  RNA  using  M-MLV  reverse  transcriptase.  After  cDNA  synthesis, 
quantitative real-time PCR was performed in 20 µL of Universal SYBR Green PCR Master Mix using 
a fluorometric thermal cycler (Corbett Research, Mortlake, NSW, Australia). Primers were designed 
using an on-line program (primer3_http://www.cgivo.2) [26]. The sequences of the sense and antisense 
primers used for amplification were as follows: SREBP-2, 5'-GTGGGACCATTCTGACCACA-3' and 
5'-GTTGTCCGCCTTTCTCCTTC-3'; HMGCR, 5'-ACTTATGGCAGCATTGGCAG-3' and 5'-ACTG 
TCGGGCTATTCAGGCT-3'; β-actin, 5'-GGACCTGACTGACTACCTCA-3' and 5'-GCACAGCTTC 
TCCTTAATGT-3'. The delta Ct method was used for relative quantification [27]. The delta Ct value 
for each sample was determined by calculating the difference between the Ct value of the target gene 
and the Ct value of the β-actin reference gene. The normalized level of expression of the target gene  
in each sample was calculated using the formula 2
−Ct. Values were expressed as fold change over  
the control. 
3.6. AMPK Activity Assay 
AMPK activity was analyzed using an AMPK Kinase Assay kit according to the manufacturer’s 
instructions. Briefly, samples were incubated for 30 min at 30 °C  in a precoated plate with a substrate 
peptide that corresponded to mouse insulin receptor substrate-1 (IRS-1). AMPK activity was measured 
by monitoring the phosphorylation of Ser 789 on IRS-1 using an anti-mouse phospho-Ser 789 IRS-1 
monoclonal antibody and peroxidase-coupled anti-mouse IgG. Conversion of the chromogenic substrate 
tetramethylbenzidine was quantified by measuring absorbance at 450 nm. Protein was determined using 
a BCA protein assay kit. Values for AMPK activity were expressed as a fold increase over the control.  
3.7. Statistical Analysis  
Values are expressed as means ±  standard errors (SE). Statistical analyses were performed using 
SPSS software version 19 (Chicago, IL, USA). Significant differences among treatment groups were 
analyzed using an unpaired Student's two-tailed t test and a one-way analysis of variance followed by 
post hoc Tukey’s multiple comparison tests. P < 0.05 was taken to indicate a significant difference. 
4. Conclusions 
We  demonstrated  that  ginsenoside  Rg3  inhibited  cholesterol  biosynthesis  and  triglyceride 
accumulation in HepG2 cells. Treatment with ginsenoside Rg3 resulted in reduced cholesterol and Int. J. Mol. Sci. 2012, 13  5738 
 
 
triglyceride levels in HepG2 cells. This study provides biochemical and genetic evidences that the 
effects of ginsenoside Rg3 on the decrease of hepatic cholesterol and triglyceride levels depend on the 
regulation of SREBP-2 and AMPK. Accordingly, ginsenoside Rg3 has great potential as a bioactive 
food ingredient for the prevention of CVD by regulating dyslipidemia. 
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